scholarly journals Core Import Price Inflation in the United States

2012 ◽  
Vol 2012 (131) ◽  
Author(s):  
Janet Koech ◽  
◽  
Mark A. Wynne ◽  
2012 ◽  
Vol 24 (4) ◽  
pp. 717-730 ◽  
Author(s):  
Janet Koech ◽  
Mark A. Wynne

2021 ◽  
Author(s):  
Elena Bobeica ◽  
Matteo Ciccarelli ◽  
Isabel Vansteenkiste

2019 ◽  
Vol 50 ◽  
pp. 51-55 ◽  
Author(s):  
Aviral Kumar Tiwari ◽  
Juncal Cunado ◽  
Abdulnasser Hatemi-J ◽  
Rangan Gupta

2017 ◽  
Vol 13 (6) ◽  
pp. e538-e542 ◽  
Author(s):  
Philip Savage ◽  
Sarah Mahmoud ◽  
Yogin Patel ◽  
Hagop Kantarjian

Purpose: The cost of cancer drugs forms a rising proportion of health care budgets worldwide. A number of studies have examined international comparisons of initial cost, but there is little work on postlicensing price increases. To examine this, we compared cancer drug prices at initial sale and subsequent price inflation in the United States and United Kingdom and also reviewed relevant price control mechanisms. Methods: The 10 top-selling cancer drugs were selected, and their prices at initial launch and in 2015 were compared. Standard nondiscounted prices were obtained from the relevant annual copies of the RED BOOK and the British National Formulary. Results: At initial marketing, prices were on average 42% higher in the United States than in the United Kingdom. After licensing in the United States, all 10 drugs had price rises averaging an overall annual 8.8% (range, 1.4% to 24.1%) increase. In comparison, in the United Kingdom, six drugs had unchanged prices, two had decreased prices, and two had modest price increases. The overall annual increase in the United Kingdom was 0.24%. Conclusion: Cancer drug prices are rising substantially, both at their initial marketing price and, in the United States, at postlicensing prices. In the United Kingdom, the Pharmaceutical Price Regulation Scheme, an agreement between the government and the pharmaceutical industry, controls health care costs while allowing a return on investment and funds for research. The increasing costs of cancer drugs are approaching the limits of sustainability, and a similar government-industry agreement may allow stability for both health care provision and the pharmaceutical industry in the United States.


2018 ◽  
Vol 21 ◽  
pp. S156
Author(s):  
I. Hernandez ◽  
C.B. Good ◽  
W.F. Gellad ◽  
N. Parekh ◽  
M. He ◽  
...  

ILR Review ◽  
2020 ◽  
pp. 001979392092896
Author(s):  
John Pencavel

Income inequality in the United States has been lower in periods when trade unionism has been strong. Using observations on wages by occupation, by geography, and by gender in collective bargaining contracts from the 1940s to the 1970s, patterns in movements of wage differentials are revealed. As wages increased, some contracts maintained relative wage differentials constant, some maintained absolute differences in wages constant, others combined these two patterns, and some did not reveal an obvious pattern. The patterns persisted even as price inflation increased in the 1970s. The dominant pattern implies a reduction in inequality as usually measured.


Sign in / Sign up

Export Citation Format

Share Document